| Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784) |
|---|
| 04/06/2005 | CN1195520C Compound antibacterial anti-inflammatory for animals and poultry |
| 04/06/2005 | CN1195517C Rationed fenmameimin drops |
| 04/06/2005 | CN1195513C Tocopherols, tocotrienols, other chroman and side chain derivatives and uses |
| 04/06/2005 | CN1195512C Use of fatty materials for prevention or reduction of microorganism adherence on skin and/or mucous membrane |
| 04/06/2005 | CN1195499C Enteric coated pharmaceutical tablet and method of manufacturing |
| 04/06/2005 | CN1195495C Emulsion preconcentrate containing cyclosporin or macrolide |
| 04/05/2005 | US6875883 Forming a phenyl-thiazoles chemical intermediates for making antioxidants, ferrielectric liquid crystal dopant, picornaviral viricides, antiinflammatory agents, anti-asthma agents, and fibringoen antagonists |
| 04/05/2005 | US6875882 Ferroelectric liquid crystals, antihistamines, antiinflammatory agents, viricides |
| 04/05/2005 | US6875871 Oxazolidinone photoaffinity probes |
| 04/05/2005 | US6875853 Immunization of dairy cattle with chimeric GapC protein against streptococcus infection |
| 04/05/2005 | US6875790 Viricides |
| 04/05/2005 | US6875789 Pyrazole-derived kinase inhibitors and uses thereof |
| 04/05/2005 | US6875784 Bactericides; grampositive, gramnegative bacteria |
| 04/05/2005 | US6875779 Cyclooxygenase inhibitor |
| 04/05/2005 | US6875777 Compounds |
| 04/05/2005 | US6875765 Inhibitors of interleukin-1 beta converting enzyme and other cysteine proteases in the ICE family |
| 04/05/2005 | US6875752 Therapy for grampositive bacteria; bactericides |
| 04/05/2005 | US6875740 Combination of a cyclic hexapeptide with antifungal drugs for treatment of fungal pathogens |
| 04/05/2005 | US6875737 Multivalent compounds for crosslinking receptors and uses thereof |
| 04/05/2005 | US6875736 Methods for identifying RNA binding compounds |
| 04/05/2005 | US6875612 Expression vector coding proteins for use in the treatment of tumors |
| 04/05/2005 | US6875599 Enzymatic protein for use in the treatment of inflammation, cancers, cardiovascular, brain, respiratory and crohn's disease |
| 04/05/2005 | US6875435 In vivo CTL elicitation by heat shock protein fusion proteins maps to a discrete domain and is CD4+ T cell-independent |
| 04/05/2005 | US6875422 Oral treatment/care agent |
| 04/05/2005 | CA2203540C Major outer membrane protein cd of moraxella |
| 04/05/2005 | CA1341478C Therapeutic methods using catalytic antibodies |
| 03/31/2005 | WO2005028528A1 3,5-dimethyl-1-adamantyl-ammonium polymeric salts and the use thereof in the form of antiviral agents |
| 03/31/2005 | WO2005028509A1 Tlr2 antagonistic antibody and use thereof |
| 03/31/2005 | WO2005028503A1 Peptide originating in hepatitis c virus |
| 03/31/2005 | WO2005028502A1 Inhibitors of serine proteases, particularly hcv ns3-ns4a protease |
| 03/31/2005 | WO2005028501A1 Macrocyclic peptides active against the hepatitis c virus |
| 03/31/2005 | WO2005028493A1 Antimicrobial derivatives |
| 03/31/2005 | WO2005028478A1 Aza-quinolinol phosphonate integrase inhibitor compounds |
| 03/31/2005 | WO2005028467A1 Antibacterial 3,5-diaminopiperidine-substitute aromatic and heteroaromatic compounds |
| 03/31/2005 | WO2005028442A2 2-pyridinone derivatives, having hiv inhibiting properties |
| 03/31/2005 | WO2005028426A1 Novel 4-phenylamino-benzaldoxime derivative and use thereof as mek inhibitor |
| 03/31/2005 | WO2005027979A2 Targeted lipid-drug formulations for delivery of drugs to myeloid and lymphoid immune cells |
| 03/31/2005 | WO2005027965A1 Antibodies against annexins, use thereof for therapy and diagnosis. use of annexins for therapy and diagnosis. |
| 03/31/2005 | WO2005027964A1 Measles subunit vaccine |
| 03/31/2005 | WO2005027936A2 Pharmaceutical compositions and therapeutical treatment with oligo-beta-(1, 3)-glucans |
| 03/31/2005 | WO2005027893A1 HUMAN β-DEFENSIN SECRETION PROMOTER |
| 03/31/2005 | WO2005027871A2 Method for production of bioresorbable microparticles microparticles thus obtained and use thereof |
| 03/31/2005 | WO2005027847A2 Antibodies for use against sars |
| 03/31/2005 | WO2005009365A3 Antibiotic product, use and formulation thereof |
| 03/31/2005 | WO2005005632A3 SMALL INTERFERING RNA SPECIFIC TO SUB-UNITS $G(A), $G(A)' AND $G(B) OF THE KINASE PROTEIN CK2, AND THE APPLICATIONS OF THE SAME |
| 03/31/2005 | WO2005004894A3 Methods for increasing cell and tissue viability |
| 03/31/2005 | WO2004092139A3 Inhibitors of cyclin-dependent kinases, compositions and uses related thereto |
| 03/31/2005 | WO2004085682A3 Caspase inhibitors, especially caspase 3 inhibitors, for the treatment of influenza |
| 03/31/2005 | WO2004076677A3 Monoclonal antibody production by ebv transformation of b cells |
| 03/31/2005 | WO2004064742A3 Methods and compositions for p2x receptor calcium entry channels and other calcium entry mechanisms |
| 03/31/2005 | WO2004039234A3 Humanized antibodies against the venezuelan equine encephalitis virus |
| 03/31/2005 | WO2004037161A3 Cyclic prodrugs of pmea one of its analogues |
| 03/31/2005 | WO2004010951A8 Method of treating tumors |
| 03/31/2005 | WO2003063897A8 Method of providing prophylaxis for tuberculosis in hiv positive individuals |
| 03/31/2005 | WO2003040329A3 Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| 03/31/2005 | WO2002042319A9 2-substituted estrogens as antiangiogenic agents |
| 03/31/2005 | US20050070719 Central nervous system disorders; antidiabetic agents; antiinflammatory agents; antiarthritic agents;obesity; osteoporosis ; anticancer agents |
| 03/31/2005 | US20050070713 Neurokinin antagonist; therapy for central nervous system disorders; psychological disorders; Parkinson's and Huntington's disease |
| 03/31/2005 | US20050070706 Antidiabetic agents; obesity; controlling appetite |
| 03/31/2005 | US20050070694 Antagonistic anti-htnfsf13b human antibodies |
| 03/31/2005 | US20050070689 Nucleotide sequences coding transmembrane activator and CAML interactor (TACI) protein for use in treatment and prevention of autoimmune disorders |
| 03/31/2005 | US20050070600 Tuberculosis therapy; mixture of cantharidic anhydride in vegetable oil; solvent extraction of plant extracts |
| 03/31/2005 | US20050070590 possessing anti-cancer activity, anti-inflammatory activity, anti-obesity activity, and/or hair growth promotion activity |
| 03/31/2005 | US20050070582 For example,1-{[2-(3,5-dimethylphenoxy)-5-nitrophenyl]sulfonyl}-4-ethylpiperazine or 1-{[2-(3,5-dichlorophenoxy)-5-nitrophenyl]sulfonyl}piperazine; for the treatment of asthma, atopic dermatitis, allergic rhinitis and other inflammatory/immunological disorders |
| 03/31/2005 | US20050070580 N-{3-[3-fluoro-4-(4-oxo-3,4-dihydro-2H-pyridin-1-yl)-phenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide; treating gram-negative organisms such as Haemophilus influenza and Moraxella catarrhalis. |
| 03/31/2005 | US20050070569 Alkyne-aryl phosphodiesterase-4 inhibitors |
| 03/31/2005 | US20050070535 Antidiabetic agents; obesity; controlling appetite |
| 03/31/2005 | US20050070531 Using such as 2-[2-(3-Amino-piperidin-1-yl)4-oxo-4H-quinazolin-3-ylmethyl]-benzonitrile to treat cancer and/or autoimmune disorder |
| 03/31/2005 | US20050070530 Dipeptidyl peptidase inhibitors |
| 03/31/2005 | US20050070526 Novel antibacterial agents |
| 03/31/2005 | US20050070523 For therapy of bacterial infection in a mammal |
| 03/31/2005 | US20050070510 Tetracycline compound of given formula, an antifungal agent such as amphotericin B and a carrier; treating fungal infections |
| 03/31/2005 | US20050070509 Metal salts such as bis(N-cyclohexyldiazeniumdioxy)copper; treating diseases associated with mycobionts; fungicides |
| 03/31/2005 | US20050070491 Immunostimulatory nucleic acid molecules |
| 03/31/2005 | US20050070486 Microspherules containing a pleuromutilin derivative |
| 03/31/2005 | US20050070480 Peptide arginals and methods for treating disseminated intravascular coagulation |
| 03/31/2005 | US20050070475 anti-viral peptide-albumin conjugate with maleimide group for bonding cysteine of albumin; for bonding mobile blood components; human immunodeficiency virus; improved half-life |
| 03/31/2005 | US20050070463 membrane proteins associated with LPSs (lipopolysaccharides), for inducing maturation of dendritic cells; membrane fraction has a proteoglycan titer, represented by the sum of the contents of galactose and of proteins, between 1.2 g/l - 3.4 g/l for galactose and between 7.5 g/l - 14.9 g/l for proteins |
| 03/31/2005 | US20050070459 treating Type I diabetes, septic shock, multiple sclerosis, inflammatory bowel disease (IBD) and Crohn's disease with BoroProline-Pinacol or other proline derivatives; dipeptidylpeptidase inhibitor |
| 03/31/2005 | US20050070005 High throughput or capillary-based screening for a bioactivity or biomolecule |
| 03/31/2005 | US20050069984 Identification of sortase gene |
| 03/31/2005 | US20050069977 Antimicrobial proteins, genes encoding the proteins and method of using the same |
| 03/31/2005 | US20050069965 Method for screening agent acting on cell wall |
| 03/31/2005 | US20050069942 Vaccine vector comprising isolated nucleic acid molecule which encodes sequence 2 linked to promoter |
| 03/31/2005 | US20050069878 Proteins associated with cell growth, differentiation, and death |
| 03/31/2005 | US20050069876 Polypeptide for use in diagnosis, treatment and prevention of cell proliferative, autoimmune, inflammatory, cardiovascular, neurological and developmental disorders. |
| 03/31/2005 | US20050069865 Synthetic hcv envelope proteins and their use for vaccination |
| 03/31/2005 | US20050069598 Antidiabetic agents; moderate glucagon-like peptide; phosphoenolpyruvate carboxykinase inhbitors; weight control |
| 03/31/2005 | US20050069592 Water-insoluble, antimicrobial silicate glass and use thereof |
| 03/31/2005 | US20050069577 Synthesis and use of reagents for improved DNA lipofection and/or slow release prodrug and drug therapies |
| 03/31/2005 | US20050069559 Lawsonia intracellularis vaccine |
| 03/31/2005 | US20050069555 Vaccine adjuvants; hepatitis c virus; modulation immunology response |
| 03/31/2005 | US20050069548 Uses of agents that bind immune system components |
| 03/31/2005 | US20050069492 As neuroprotective agents in the therapy of neuronal disorders of the central and peripheral nervous systems |
| 03/31/2005 | DE10341518A1 Pharmazeutischer Wirkstoff gegen Hepatitis Pharmaceutical drug for hepatitis |
| 03/31/2005 | DE10340845A1 Pharmazeutisches Kombinationspräparat, enthaltend Glycyrrhizinsäure, Zink und eine Verbindung, die eine Thiolgruppe oder eine zu dieser metabolisierbare Gruppe enthält A pharmaceutical combination preparation containing glycyrrhizic acid, zinc and a compound containing a thiol group or a metabolizable to this group |
| 03/31/2005 | CA2540329A1 2-pyridinone derivatives, having hiv inhibiting properties |
| 03/31/2005 | CA2539789A1 Peptide originating in hepatitis c virus |
| 03/31/2005 | CA2539074A1 Campylobacter polypeptides and methods of use |
| 03/31/2005 | CA2538991A1 Treatment of severe distal colitis |